Day: November 2, 2022

Robins, Roland K. published an article in 1957, the title of the article was Potential purine antagonists. IX. Further studies of some 4,6-disubstituted-pyrazolo[3,4-d]pyrimidines.Application In Synthesis of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine And the article contains the following content:

[The 4,6-disubstituted-pyrazolo[3,4-d]pyrimidines are represented in this abstract by Z, followed in parentheses by the 4- and the 6-substituent, resp.] Powd. Z(HO,HO) (I) (200 g.), 1300 cc. POCl3, and 500 cc. PhNEt2 refluxed 2 hrs., about 900 cc. excess POCl3 removed in vacuo on the steam bath, the sirupy residue poured with stirring onto crushed ice and H2O and extracted with Et2O, the extract evaporated, the residue (128 g.) extracted 5 hrs. in a Soxhlet apparatus with 250 cc. dry C6H6 and 250 cc. cyclohexane, the extract concentrated to 200 cc., and poured slowly with stirring into 1 l. petr. ether, and the precipitate recrystallized from C6H6-heptane yielded 105 g. Z(Cl, Cl) (II), m. 145° (decomposition). II (40 g.) added during 15 min. in portions to 400 cc. boiling 2N KOH with stirring, the mixture boiled with C, stirred 15 min., filtered, acidified with AcOH, cooled to 30°, and filtered, and the filtrate refrigerated 48 hrs. yielded 24.1 g. Z(HO, Cl) (III), m. above 300°; also obtained in 60% yield by refluxing the Z(MeS, Cl) (IV) with N NaOH. Z(HS, HO) (135 g.) stirred 1 hr. with 100 g. KOH and 3 l. H2O, treated with 115 cc. MeI, stirred 45 min., warmed to 50°, neutralized with AcOH, and filtered gave 120 g. Z(MeS, HO) (V). V (108 g.), 1200 cc. POCl3, and 100cc. PhNMe2 refluxed 1 hr. and worked up in the usual manner yielded 49.5 g. IV, m. 200-1° (decomposition) (PhMe) II (4.0 g.) added at 0° to 5.0 g. KOH, 100 cc. MeOH, and 20 cc. MeSH, the mixture kept 15 min. at 0°, diluted with 50 cc. ice H2O, acidified immediately with AcOH, and filtered gave 3.5 g. IV. Z(HS, Cl) (VI) (5.0 g.) added at 10° to 4.4 g. NaOH in 100 cc. H2O, shaken 10 min. with 6 g. MeI, stirred with C, filtered, acidified with AcOH, and filtered yielded 3.6 g. crude IV. Powd. II (5.0 g.) added at 0° to 200 cc. 0.5N NaOH previously saturated with H2S, stirred 15 min. at 0°, warmed to 10°, treated with C, filtered, acidified with AcOH, and filtered yielded 4.9 g. VI. II (5.0 g.) heated 20 min. on the steam bath with 75 cc. 25% aqueous MeNH2 and filtered hot gave 3.9 g. Z(MeNH, Cl) (VII), m. above 300°, also obtained in 85% yield from IV and aqueous MeNH2. Z(MeO, Cl) (VIII) and aqueous MeNH2 gave 80% VII. II (6.0 g.) added in small portions to 5.0 g. Na in 150 cc. absolute MeOH, warmed, filtered, and evaporated in vacuo, and the residue diluted with 100 cc. H2O, acidified with AcOH, cooled overnight, and filtered gave 4.8 g. VIII, m. 181-2° (C6H6). II (5 g.) and EtONa in EtOH gave similarly Z(EtO, Cl), m. 212-14° (C6H6). IV (2.0 g.) heated 0.5 hr. on the steam bath with 5 g. KOH, 10 cc. MeSH, and 100 cc. H2O, acidified with AcOH, and filtered gave 1.1 g. Z(MeS, MeS) (IX), m. 197-8° (PhMe). II (5.0 g.), 10 g. KOH, 100 cc. H2O, and 15 cc. MeSH heated 4 hrs. on the steam bath, acidified with AcOH, and filtered gave IX. II (5.0 g.) and NaOMe in MeOH refluxed 36 hrs. on the steam bath, concentrated to 50 cc., diluted with 100 cc. H2O, acidified with AcOH, and cooled yielded 3.2 g. Z(MeO, MeO), m. 222-3° (C6H6-EtOH). III (10 g.) and 100 cc. alc. NH3 heated 12 hrs. in a bomb at 200°, cooled, and filtered, the residue dissolved in 300 cc. boiling H2O with concentrated HCl, and the solution adjusted with NH4OH to pH 9 and filtered hot gave 7.6 g. Z(HO, H2N) (X). X (6 g.), 25 g. P2S5, and 300 cc. pyridine refluxed 3 hrs., cooled, and filtered, the residue added to 500 cc. H2O, heated on the steam bath overnight, treated with 50 cc. concentrated NH4OH, heated on the steam bath, cooled, and filtered, and the residue added to 700 cc. boiling H2O, dissolved with concentrated NH4OH, boiled with C, filtered hot, and reprecipitated with AcOH gave 4.1 g. Z(HS, H2N), light green needles, m. above 300°. III (2 g.) and 4.0 g. CS(NH2)2 heated 4 hrs. with 100 cc. absolute EtOH, cooled, and filtered gave Z(HO, HS). Powd. II (5 g.) carefully added to 150 cc. 20-40% aqueous primary amine, heated 10-30 min. on the steam bath, cooled, and filtered gave the corresponding 4-substituted-amino-6-chloropyrazolo[3,4-d]pyrimidine (XI) (method A). The appropriate amine (10-15 g.) in absolute EtOH treated with 5.0 g. II, heated 15-30 min. on the steam bath, cooled, and filtered gave the corresponding XI (method B). By these methods were prepared the following XI (substituent, method of preparation, and % yield given): Me (XII), A, 84; iso-Pr, A, 92; Et, A, 80; Pr, A, 95; iso-Bu, A, 83; PhCH2 (XIII), B, 78; CH2CH2OH, A, 60; cyclohexyl, B, 73; 1-C10H7, B, 70. II (1 g.) and 150 cc. 30% aqueous MeNH2 heated 12 hrs. on the steam bath, treated with more MeNH2, heated again 12 hrs., and cooled overnight gave 0.7 g. Z(MeNH, MeNH) (XIV), m. 248-50° (H2O). Similarly were prepared the following Z(RNH, RNH) (XV) (R, % yield, and m.p. given): Me, 78, 249-50° (EtOH); Et, 85, 238-40° (aqueous EtOH); Bu, 73, 182-3° (aqueous EtOH); Pr, 62, 194-5° (aqueous EtOH); CH2CH2OH, 56, 214-15° (H2O). III (2 g.) and 150 cc. 40% aqueous MeNH2 heated 8 hrs. on the steam bath, treated with an addnl. 100 cc. 40% aqueous MeNH2, and heated again 8 hrs., this treatment repeated once more, and the mixture cooled and filtered gave 62% Z(HO, MeNH). Similarly were prepared the following Z(HO, NRR’)(R, R’, and % yield given): H, Pr, 76 (aqueous EtOH); H, NH2 (hemihydrate), 70 (aqueous EtOH); Me, Me, 67 (aqueous HCONMe2); H, Me2N(CH2)3(di-HCl salt), 86 (EtOH). XIII (2.0 g.) and 100 cc. 30% aqueous Me2NH heated 8 hrs. on the steam bath, treated with 100 cc. aqueous Me2NH, heated 16 hrs., cooled, and filtered gave 1.5 g. Z(PhCH2NH, Me2N), m. 255-6° (EtOH). II (12.0 g.) and 100 cc. absolute alc. NH3 heated 12 hrs. at 100° in a bomb, cooled, and filtered, the residue washed with H2O, suspended in 800 cc. boiling H2O, dissolved by the addition of KOH, boiled 10 min. with C, and filtered hot, and the filtrate acidified with AcOH and filtered yielded 6.4 g. Z(H2N, Cl) (XVI), decompose gradually above 250°. XII (3 g.) and 150 cc. 20% aqueous Me2NH heated 8 hrs. on the steam bath, treated with an addnl. 100 cc. aqueous Me2NH, heated again 8 hrs., filtered, and cooled yielded 1.9 g. Z(MeNH, Me2N) (XVII), m. 272-3° (aqueous EtOH). VIII (2 g.) and alc. NH3 heated 8 hrs. at 100° in a bomb gave 1.1 g. XVI, also obtained under similar conditions from IV. II (5.0 g.), 10 g. CS(NH2)2, and 150 cc. EtOH refluxed 3 hrs. on the steam bath, cooled, and filtered gave 4.1 g. Z(HS, HS) (XVIII). VI (2 g.) and 100 ml. aqueous Me2NH heated 6 hrs. on the H2O bath gave 1.8 g. crude Z(HS, Me2N) (XVIII). Z(HO, Me2N) (3 g.) and 15 g. P2S5 refluxed 6 hrs. with 500 cc. pyridine, and evaporated in vacuo on the steam bath, the residue warmed with 300 cc. H2O on the steam bath, cooled, and filtered, and the residue reprecipitated from hot dilute base with AcOH yielded 0.8 g. XVIII. IV (3 g.) and 100 cc. concentrated NH4OH heated 8 hrs. at 100° in a bomb, cooled, and filtered gave 2.5 g. (crude) Z(H2N, MeS) (XIX), m. 297-8° (EtOH). Z(Cl, MeS) (3 g.), m. 178-9° (decomposition), and 100 cc. concentrated NH4OH yielded similarly 2.6 g. XIX. XIX (1 g.) in 250 cc. boiling H2O and 3 cc. HCl treated with 3 g. NaNO2, heated 10 min. on the steam bath, cooled, and filtered gave 0.4 g. Z(HO, MeS). XIX (1.5 g.), 100 cc. H2O, 10 cc. concentrated HCl, and 10 cc. 30% H2O2 boiled 20 min., neutralized with concentrated NH4OH, and filtered yielded 0.8 g. Z(H2N, HO), Rf 0.036 (PrOHNH4OH), 0.50 (concentrated HCl-iso-PrOH-H2O). VIII (2 g. and 100 cc. 30% aqueous MeNH2 heated 4 hrs. on the steam bath, cooled, and filtered yielded 1.2 g. Z(MeNH, MeS) (XX), m. 253-4° (aqueous EtOH). IX (1.5 g.) and 100 cc. 30% aqueous MeNH2 heated 4 hrs. on the steam bath gave similarly 0.9 g. XX, m. 254-5° (aqueous EtOH). Z(Cl, MeS) (3 g.) and 150 cc. 30% aqueous MeNH2 gave 1.7 g. XX. Z(MeO, MeS) (2 g.) and 130 cc. 30% aqueous Me2NH heated 1 hr. on the steam bath, cooled, and filtered yielded 1.1 g. Z(Me2N, MeS) (XXI), m. 262-5° (aqueous EtOH). IX (1.5 g.) and 100 cc. 30% aqueous Me2NH heated 3 hrs. on the steam bath gave 0.8 g. XXI. II (3 g.), 3 g. NaOH, and 15 cc. EtSH in 100 cc. EtOH kept 0.5 hr. at room temperature, acidified with AcOH, and filtered gave 1.6 g. Z(EtS, Cl), m. 149-50° (C6H6-heptane). Z(HS, H2N) (1 g.) in 30 cc. H2O containing 2.0 g. NaOH stirred 20 min. with 0.5 cc. Me2SO4, acidified with AcOH, and stored gave 0.8 g. Z(MeS, H2N), m. 240-1° (H2O). II (6 g.) and 50 cc. absolute alc. NH3 heated 24 hrs. at 200° in a bomb, the solution evaporated to dryness on the steam bath, the residue dissolved with 5 g. NaOH and 100 cc. H2O, and the solution boiled with C, neutralized with AcOH, filtered, and kept gave Z(H2N, H2N), also obtained similarly from IV or Z(Cl, MeS). The ultraviolet absorption maximum of the various XI and XV are listed. The experimental process involved the reaction of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine(cas: 98138-75-1).Application In Synthesis of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine

6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine(cas:98138-75-1) belongs to pyrazoles-derivatives. The use of pyrazole derivatives is based on their analgesic, anti-inflammatory, antipyretic, antiarrhythmic, sedative, muscle relaxant, neuroleptic, anticonvulsant, monoamine oxidase inhibitory, antidiabetic and antibacterial activities.Application In Synthesis of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Robins, Roland K. published an article in 1956, the title of the article was Potential purine antagonists. I. Synthesis of some 4,6-substituted pyrazolo[3,4-d]pyrimidines.Safety of 4-Chloro-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine And the article contains the following content:

EtOCH2CH(CN)2 (150 g.) added in 3-5-g. portions to 100 g. 85% N2H4.H2O with slight cooling, the mixture heated 1 hr. on the steam bath, diluted with 100 cc. H2O, and refrigerated overnight, the mushy solution filtered, and the solid washed with cold H2O yielded 97 g. 3-amino-4-cyanopyrazole (I), m. 174-5° (from H2O). I (0.5 g.) refluxed 8 hrs. with 100 cc. AcCl and evaporated to dryness on the steam bath, and the residue dissolved in 25 cc. boiling H2O, neutralized with NH4OH, and cooled gave 0.4 g. Ac derivative of I, m. 221-2° (from H2O). Finely powd. I (50 g.) added with stirring below 40° to 170 cc. concentrated H2SO4 (cooled to 20°) during 0.5 hr., and the solution stirred 1 hr. at room temperature, poured with stirring into 500 cc. H2O and 250 cc. ice, refrigerated overnight, and filtered yielded 67.0 g. 3-amino-4-pyrazolecarboxamide-0.5H2SO4 (II) (II.0.5H2SO4), m. 222-5° (from H2O). II.0.5H2SO4 (3 g.) in 50 cc. H2O adjusted with NH4OH to pH 9 and allowed to stand 3 days deposited 1.1 g. II, m. 187-9° (from H2O). II.0.5H2SO4 (75 g.) and 200 cc. HCONH2 heated 45 min. at 180-90°, cooled, diluted with 1 l. cold H2O, and filtered yielded 48.0 g. 4-hydroxypyrazolo[3,4-d]pyrimidine (III). II.0.5H2SO4 (100 g.) and 200 g. urea heated 20 min. at 160° and then 20 min. at 190° and dissolved in hot dilute aqueous NaOH, the boiling basic solution carefully acidified with AcOH and filtered after 10 min. yielded 74 g. 90-5% pure 4,6-di-OH analog (IIIa) of III. I (35 g.) and 70 g. CS(NH2)2 heated 0.5 hr. at 180° and 10 min. at 200°, cooled, and dissolved in hot dilute aqueous NaOH, the hot solution treated with C, and the boiling filtrate carefully acidified with glacial AcOH yielded 26.0 g. 4-amino-6-mercaptopyrazolo[3,4-d]pyrimidine (IV), light tan material. II.0.5H2SO4 (50 g.) with 100 g. CS(NH2)2 gave similarly 24.0 g. 4-OH analog (V) of IV. Dry III (10 g.) added to 300 cc. POCl3, the mixture refluxed 1.5 hrs. with 30 cc. PhNMe2, the excess POCl3 removed in vacuo, the sirupy residue poured with stirring into 100 cc. H2O and 400 g. crushed ice and extracted with Et2O, and the extract worked up gave 9.8 g. 4-chloropyrazolo[3,4-d]pyrimidine (VI), decomposed at 130-5° (from C6H6). III (10 g.) finely powd. and mixture with 50 g. P2S5, the mixture added in small portions with stirring to 300 cc. Tetralin at 165° during 0.5 hr., the mixture heated 4 hrs. with stirring at 190-5°, cooled, and filtered, the filter residue washed with petr. ether, dried, added carefully to 1 l. H2O at 80°, boiled 10 min., and treated with enough KOH to effect solution, the solution stirred with C and filtered, and the hot filtrate acidified with AcOH gave 10.1 g. 4-mercaptopyrazolo[3,4-d]pyrimidine (VII), white crystals, m. above 360° (from 30% EtOH). VI (2 g.) and 2 g. CS(NH2)2 refluxed 2 hrs. with 100 cc. absolute EtOH cooled and filtered gave 1.6 g. crude VII. VI (3 g.) in 150 cc. concentrated NH4OH concentrated on the steam bath to 50 cc., diluted with 200 cc. concentrated NH4OH, concentrated on the steam bath to 150 cc., boiled with C, filtered, and cooled gave 0.85 g. 4-aminopyrazolo[3,4-d]pyrimidine (VIII), colorless needles. I (30 g.) boiled 0.5 hr. with 60 cc. HCONH2, cooled, diluted with 100 cc. cold H2O, and filtered, the residue suspended in 400 cc. hot H2O, treated with 50 cc. concentrated HCl, boiled 15 min. with C, and the hot filtrate adjusted to pH 8 with concentrated NH4OH and cooled to room temperature gave 21.0 g. VIII, colorless solid. VI (5.0 g.) and alc. NH3 heated 12 hrs. at 100° in a bomb and filtered, and the crude residue dissolved in dilute HCl and reprecipitated with NH4OH gave 3.9 g. VIII. IIIa (10 g.) and 30 cc. PhNMe2 refluxed 1 hr. with 250 cc. POCl3, the mixture worked up in the usual manner, and the product isolated with Et2O gave 2.4 g. compound C12H10ClN4(sic), light yellow needles, m. 225-7° (from xylene). V (14 g.) and 10 g. NaOH in 300 cc. H2O shaken 10 min. at 5° with 12 g. MeI, charcoaled, filtered, and acidified with AcOH yielded 12.0 g. 4-hydroxy-6-methylmercaptopyrazolo[3,4-d]pyrimidine (IX). I (10 g.) heated 20 min. with 20 g. urea at 180-200°, the cooled solid dissolved in 2N NaOH, the solution boiled gently 10 min. with C, and the boiling filtrate acidified with glacial AcOH gave 4-amino-6-hydroxypyrazolo[3,4-d]-pyrimidine which was purified by reprecipitation IX (22.0 g.), 400 cc. POCl3, and 30 cc. PhNMe2 refluxed 0.5 hr. gave 16 g. 4-Cl analog of IX, m. 178-9° (decomposition) (from heptane). VII (5 g.) in 65 cc. 0.8N NaOH shaken 15 min. at 20° with 5.0 g. MeI, treated with C, filtered, and acidified with AcOH, the crude precipitate suspended in 100 cc. H2O and adjusted with NH4OH to pH 9 and filtered, and the residue washed and recrystallized from H2O yielded 4.1 g. 4-MeS analog of VII, m. 193°. IIIa (15 g.) and 80 g. P2S5 refluxed 4 hrs. with 900 cc. dry pyridine and evaporated in vacuo on the steam bath, the residue diluted with 600 cc. ice H2O, allowed to stand 0.5 hr. at room temperature, heated 2 hrs. on the steam bath, the solution refrigerated overnight, and the crude precipitate reprecipitated with AcOH from boiling aqueous alkali gave 12.6 g. 4-mercapto-6-hydroxypyrazolo[3,4-d]pyrimidine, light green needles. V (15 g.) and 65 g. P2S5 in 900 cc. dry pyridine gave similarly 12.0 g. 4,6-dimercaptopyrazolo[3,4-d]pyrimidine, light green solid. Finely powd. VI (4.5 g.) in 150 cc. H2O and 4 cc. concentrated NH4OH hydrogenated about 6 hrs. at 20 lb. pressure over 1.0 g. 10% Pd-C and filtered, the residue extracted with 100 cc. boiling H2O, the combined filtrates evaporated to dryness on the steam bath, the residue extracted 18 hrs. with 200 cc. PhMe in a Soxhlet apparatus, the extract evaporated, and the residue sublimed at 180-200° and 15 mm. yielded 2.65 g. pyrazolo[3,4-d]pyrimidine (X), colorless needles, m. 213-14°. VI (3.0 g.) heated 1 hr. on the steam bath with 0.6 g. Na dissolved in 30 cc. absolute EtOH, diluted with 20 cc. H2O, and neutralized with AcOH gave 1.3 g. 4-EtO derivative of X, m. 168-9°. 4-Cl analog (XI) of X (7.0 g.) in 150 cc. EtOH and 10 cc. concentrated NH4OH hydrogenated 24 hrs. over 2.7 g. Pd-C at 20 lb. pressure, filtered, and evaporated to dryness on the steam bath yielded 1.7 g. 6-methylmercaptopyrazolo[3,4-d]pyrimidine, white crystals, m. 210-12° (from 80% EtOH). XI (4.0 g.) heated 4 hrs. on the steam bath with 1.0 g. Na in 75 cc. absolute MeOH, neutralized with glacial AcOH, and cooled gave 3.1 g. 4-MeO analog of IX, m. 193-4° (from aqueous MeOH). VI (5-10 g.) added to 50-100 cc. of a 25-40% aqueous solution of a primary or secondary amine, heated 4 hrs. on the steam bath, refrigerated overnight, and filtered, and the residue washed with a little ice water and recrystallized gave the corresponding N-substituted-4-aminopyrazolo[3,4-d]pyrimidines (XII) (method A); VI (5-10 g.) added to about 0.15 mole primary or secondary amine in 150 cc. absolute EtOH, heated 4 hrs. on the steam bath, cooled overnight and filtered, and the crude product recrystallized gave the corresponding XII (method B) (N-substituents, m.p., % yield, and method given): H, Me, 227-8° (from H2O), 83, A; Me, Me, 233-4° (from C6H6-EtOH), 61, A; Et, Et, 186-7° (from aqueous EtOH), 85, A; H, iso-Pr, 253-4° (from H2O), 70, A; H, Ph, 263-4° (from EtOH), 55, B; H, PhCH2, 215-17° (from aqueous EtOH), 78, B; H, Et, 259-60° (from aqueous EtOH), 77, A; H, 1-furylmethyl, 223-5° (from EtOH), 82, B; Me, Ph, 234-6° (from EtOH), 63, B; H, Bu, 205-6° (from aqueous EtOH), 75, B; H, o-MeC6H4, 260-1° (from EtOH), 85, B. XI gave similarly the 6-MeS derivatives of XII (N-substituents, m.p., % yield, and method given): H, H, above 300° (from H2O), 58, A; Me, Me, 263-5° (aqueous EtOH), 45, A; H, NH2, above 300° (from H2O), 30, A; H, (CH2)2NEt2, 130-2° (from EtOH), 35, B. The solubilities of a number of 4,6-disubstituted-pyrazolo[3,4-d]pyrimidines (XIII) are tabulated (4 and 6-substituents, and solubility in H2O at 100° in parts of H2O necessary to dissolve 1 part XIII given): OH, H, 190; OH, OH, 800; NH2, H, 1000; MeNH, H, 10; Me2N, H, 10; SH, H, 500; H, MeS, 350; MeS, H, 300; H, H, 200 (at 30°). The ultraviolet absorption maximum of the various XIII described at pH 1 and 11 are listed. The experimental process involved the reaction of 4-Chloro-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine(cas: 85426-79-5).Safety of 4-Chloro-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine

4-Chloro-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine(cas:85426-79-5) belongs to pyrazoles-derivatives. The use of pyrazole derivatives is based on their analgesic, anti-inflammatory, antipyretic, antiarrhythmic, sedative, muscle relaxant, neuroleptic, anticonvulsant, monoamine oxidase inhibitory, antidiabetic and antibacterial activities.Safety of 4-Chloro-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Ashok, Dongamanti; Kavitha, Rangu; Gundu, Srinivas; Sarasija, Madderla published an article in 2019, the title of the article was Microwave-assisted synthesis and antimicrobial evaluation of 6-[3-aryl-1-phenyl-4′,5′-dihydro[4,5′-bi-1H-pyrazol]-3′-yl]–2H-chromen-5-ols.Quality Control of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde And the article contains the following content:

A new series of 6-[3-aryl-1-phenyl-4′,5′-dihydro[4,5′-bi-1H-pyrazol]-3′- -yl]-2H-chromen-5-ol derivatives was synthesized by Michael addition of chal- cones 5a-j with hydrazine hydrate in presence of sodium acetate under con- ventional heating and microwave irradiation Structural assignment of the products was confirmed based on IR, 1H-NMR, 13C-NMR, MS and anal. data. All the synthesized compounds 6a-j were screened for their antimicrobial activity against various bacterial and fungal strains. Most of the compounds exhibited variable range of antimicrobial activity and compounds 6c-f and 6i showed promising antimicrobial potency. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).Quality Control of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde

The Article related to pyrazole pyrazoline derivative microwave irradiation conventional heating antimicrobial, Pharmaceuticals: Drug Standards and other aspects.Quality Control of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On April 10, 2008, Elzein, Elfatih; Kalla, Rao V.; Li, Xiaofen; Perry, Thao; Gimbel, Art; Zeng, Dewan; Lustig, David; Leung, Kwan; Zablocki, Jeff published an article.COA of Formula: C9H7N3O2 The title of the article was Discovery of a Novel A2B Adenosine Receptor Antagonist as a Clinical Candidate for Chronic Inflammatory Airway Diseases. And the article contained the following:

Recently, the authors have reported a series of new 1,3-sym. (R1 = R3) substituted xanthines which have high affinity and selectivity for the human adenosine A2B receptors (hA2B-AdoR). Unfortunately, this class of compounds had poor pharmacokinetic properties. This prompted us to investigate the effect of differential alkyl substitution at the N-1 and N-3 positions (N1-R ≠ N3-R) on A2B-AdoR affinity and selectivity; the authors had the dual objectives of enhancing affinity and selectivity for the A2B-AdoR, as well as improving oral bioavailability. This effort has led to the discovery of compound (I), that displayed high affinity and selectivity for the hA2B-AdoR (Ki = 22 nM). In addition, compound I showed high functional potency in inhibiting the accumulation of cAMP induced by 5′-N-ethylcarboxamidoadenosine in HEK-A2B-AdoR and NIH3T3 cells with KB values of 6 and 2 nM, resp. In a single ascending-dose phase I clin. study, compound I had no serious adverse events and was well tolerated. The experimental process involved the reaction of 1-(Pyridin-3-yl)-1H-pyrazole-4-carboxylic acid(cas: 1014631-89-0).COA of Formula: C9H7N3O2

The Article related to adenosine receptor antagonist preparation antiinflammatory inflammatory airway disease pharmacokinetics, Pharmacology: Structure-Activity and other aspects.COA of Formula: C9H7N3O2

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Kamal, Raj; Kumar, Vipan; Kumar, Ravinder; Bhardwaj, Jitender K.; Saraf, Priyanka; Kumari, Priya; Bhardwaj, Vikas published an article in 2017, the title of the article was Design, Synthesis, and Screening of Triazolopyrimidine-Pyrazole Hybrids as Potent Apoptotic Inducers.HPLC of Formula: 36640-53-6 And the article contains the following content:

An efficient synthesis of novel 3-(3-aryl-1-phenyl-1H-pyrazol-4-yl)-5,7-dimethyl-[1,2,4]triazolo[4,3-a]-pyrimidines was accomplished by the oxidation of pyrimidinylhydrazones by using organoiodine(III) reagent. All new triazolopyrimidine derivatives bearing the pyrazole scaffold were screened to evaluate them as a reproductive toxicant in the testicular germ cells of goat (Capra hircus). This study aimed at assessing the cytol. and biochem. changes in testicular germ cells after the exposure to triazolopyrimidines in a dose- and time-dependent manner. Histomorphol. anal., fluorescence assays, apoptosis quantification, and terminal deoxynucleotidyl transferase dUTP-mediated nick-end labeling (TUNEL) assays were performed to determine cytol. changes, whereas thiobarbituric acid-reactive substance (TBARS) and ferric reducing antioxidant power (FRAP) assays were carried out to measure the oxidative stress in triazolopyrimidines treated germ cells. The parallel use of these methods enabled us to determine the role of triazolopyrimidines in inducing apoptosis as a consequence of cytogenetic damage and oxidative stress generated in testicular germ cells of goat. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).HPLC of Formula: 36640-53-6

The Article related to screening triazolopyrimidine pyrazole apoptosis inducer, cytotoxic activity, pyrazole, synthesis, triazole, Pharmacology: Structure-Activity and other aspects.HPLC of Formula: 36640-53-6

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On May 14, 2015, Hatcher, John M.; Zhang, Jinwei; Choi, Hwan Geun; Ito, Genta; Alessi, Dario R.; Gray, Nathanael S. published an article.Synthetic Route of 98138-75-1 The title of the article was Discovery of a Pyrrolopyrimidine (JH-II-127), a Highly Potent, Selective, and Brain Penetrant LRRK2 Inhibitor. And the article contained the following:

Activating mutations in leucine-rich repeat kinase 2 (LRRK2) are present in a subset of Parkinson’s disease (PD) patients and may represent an attractive therapeutic target. Here the authors report JH-II-127 I, as a potent and selective inhibitor of both wild-type and G2019S mutant LRRK2. Compound I substantially inhibits Ser910 and Ser935 phosphorylation of both wild-type LRRK2 and G2019S mutant at a concentration of 0.1-0.3 μM in a variety of cell types and is capable of inhibiting Ser935 phosphorylation in mouse brain following oral delivery of doses as low as 30 mg/kg. The experimental process involved the reaction of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine(cas: 98138-75-1).Synthetic Route of 98138-75-1

The Article related to pyrrolopyrimidine brain penetrant lrrk inhibitor, lrrk2, parkinson’s disease, leucine-rich repeat kinase 2, pharmacokinetics, Pharmacology: Structure-Activity and other aspects.Synthetic Route of 98138-75-1

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On April 3, 2018, Naim, Mohd. Javed; Alam, Ozair; Alam, Jahangir Md.; Shaquiquzzaman, Mohammad; Alam, Mumtaz Md.; Naidu, Vegi Ganga Modi published an article.Recommanded Product: 36640-53-6 The title of the article was Synthesis, docking, in vitro and in vivo antidiabetic activity of pyrazole-based 2,4-thiazolidinedione derivatives as PPAR-γ modulators. And the article contained the following:

The design, synthesis, structure-activity relationship, and biol. activity of 2,4-thiazolidinedione derivatives as peroxisome proliferator-activated receptor-γ (PPAR-γ) modulators for antidiabetic activity are reported. Fifteen 2,4-thiazolidinedione derivatives clubbed with pyrazole moiety were docked into the ligand binding domain of PPAR-γ by the Glide XP module of Schrodinger. Eight derivatives (5a (5-((3-(3,4-dichlorophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)thiazolidine-2,4-dione), 5b (5-((1-phenyl-3-(thien-2-yl)-1H-pyrazol-4-yl)methylene)thiazolidine-2,4-dione), 5d, 5f, 5i, 5l, 5n, 5o) having Glide XP scores > -8 as compared to the standard drug, rosiglitazone (Glide XP score = -9.165), showed almost similar interaction with the amino acids such as HIS 449, TYR 473, TYR 327, HIS 323, and SER 289 in the mol. docking studies. These eight derivatives were further screened for PPAR-γ transactivation and in vivo blood glucose lowering activity in the streptozotocin-induced diabetic rat model. Compounds 5o, 5n, 5a, 5i, and 5b showed 52.06, 51.30, 48.65, 43.13, and 40.36% PPAR-γ transactivation as compared to the reference drugs rosiglitazone and pioglitazone with 85.30 and 65.22% transactivation, resp. The data anal. showed significant blood glucose lowering effects (hypoglycemia) of compounds 5o, 5n, and 5a (140.1±4.36, 141.4±6.15, and 150.7±4.15, resp.), along with reference drugs pioglitazone (135.2±4.91) and rosiglitazone (141.1±5.88) as compared to the diabetic control. Furthermore, the most potent compound 5o also elevated the PPAR-γ gene expression by 2.35-fold as compared to rosiglitazone (1.27-fold) and pioglitazone (1.6-fold). It also significantly lowered the AST, ALT, and ALP levels and caused no damage to the liver. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).Recommanded Product: 36640-53-6

The Article related to pyrazole thiazolidinedione preparation ppar gamma modulator docking antidiabetic diabetes, ppar-γ, diabetes, molecular docking, thiazolidinedione, Pharmacology: Structure-Activity and other aspects.Recommanded Product: 36640-53-6

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On August 31, 2017, Naim, Mohd. Javed; Alam, Jahangir Md.; Nawaz, Farah; Naidu, V. G. M.; Aaghaz, Shams; Sahu, Meeta; Siddiqui, Nadeem; Alam, Ozair published an article.SDS of cas: 36640-53-6 The title of the article was Synthesis, molecular docking and anti-diabetic evaluation of 2,4-thiazolidinedione based amide derivatives. And the article contained the following:

A series of thiazolidinedione based amide derivatives were designed, synthesized and docked against the PPARγ receptor target. 11 Compounds from the series with good glide scores were selected for in vivo antidiabetic study based on streptozotocin induced diabetic rat model. It was observed that 4 compounds (I, II, III & IV) showed significantly good antidiabetic activity in comparison to rosiglitazone and pioglitazone as reference drugs. Compound I appeared as the most potent derivative in lowering blood glucose level and showed excellent interaction with SER 342, ILE 281, pi-pi interaction with ARG 288 and halogen bond interaction with LYS 367. Further, PPARγ transactivation and gene expression studies of compound I were carried out to investigate the possible mechanism of action through PPARγ modulation. Compound I exhibited 53.65% transactivation and elevated PPARγ gene expression by 2.1 folds. The biochem. parameters (AST, ALT and ALP levels) were found within the range with no noteworthy damage to liver. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).SDS of cas: 36640-53-6

The Article related to thiazolidinedione amide derivative synthesis sar antidiabetic pharmacokinetics toxicity, antidiabetic, molecular docking, pparγ, thiazolidinedione, Pharmacology: Structure-Activity and other aspects.SDS of cas: 36640-53-6

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On April 21, 2011, Bretschneider, Thomas; Fuesslein, Martin; Koehler, Adeline; Muehlthau, Friedrich August; Franken, Eva-Maria; Voerst, Arnd published a patent.Computed Properties of 1014631-89-0 The title of the patent was Synthesis of 1-(pyrid-3-yl)-pyrazoles and 1-(pyramid-5-yl)-pyrazoles and use as insecticide and/or acaricide.. And the patent contained the following:

The invention relates to the use of partially known heterocyclic compounds for combating animal pests, including arthropods and in particular insects, and further relates to novel heterocyclic compounds and to methods for synthesis thereof. Also disclosed are the rates of effectiveness of selected compounds, relating to the invention, in killing particular insect and acarid pests on sample crops. The experimental process involved the reaction of 1-(Pyridin-3-yl)-1H-pyrazole-4-carboxylic acid(cas: 1014631-89-0).Computed Properties of 1014631-89-0

The Article related to pyridyl pyramidyl pyrazole insecticide acaricide crop protection, Agrochemical Bioregulators: Invertebrate and other aspects.Computed Properties of 1014631-89-0

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Verma, Anil; Kumar, Vinod; Khare, Rajshree; Singh, Joginder published an article in 2019, the title of the article was Synthesis of some hippuric acid substrate linked novel pyrazoles as antimicrobial agents.Category: pyrazoles-derivatives And the article contains the following content:

Escalating resistance of microorganisms to the currently accessible antimicrobial drugs has forced to synthesize some novel biol. active compounds as efficient alternates via economical substrates. Hence, hippuric acid was used as one of the starting materials to synthesize pyrazole derivatives All the synthesized compounds were characterized by IR, NMR (1H & 13C) and mass spectral data. The antimicrobial potential of synthesized compounds has been explored against four bacterial and two fungal strains. Among the 12 compounds, 3 compounds 8j, 8k and 8l were found to exhibit prominent antimicrobial potential as compared with the standards ciprofloxacin and amphotericin-B. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).Category: pyrazoles-derivatives

The Article related to hippuric acid antimicrobial pyrazoles, Placeholder for records without volume info and other aspects.Category: pyrazoles-derivatives

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics